AU2017283720C1 - Preparation of factor Xa derivatives - Google Patents

Preparation of factor Xa derivatives Download PDF

Info

Publication number
AU2017283720C1
AU2017283720C1 AU2017283720A AU2017283720A AU2017283720C1 AU 2017283720 C1 AU2017283720 C1 AU 2017283720C1 AU 2017283720 A AU2017283720 A AU 2017283720A AU 2017283720 A AU2017283720 A AU 2017283720A AU 2017283720 C1 AU2017283720 C1 AU 2017283720C1
Authority
AU
Australia
Prior art keywords
seq
acid sequence
amino acid
heavy chain
chain consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2017283720A
Other languages
English (en)
Other versions
AU2017283720B2 (en
AU2017283720A1 (en
Inventor
Pamela B. Conley
Mark KARBARZ
Genmin Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017283720(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2017283720A1 publication Critical patent/AU2017283720A1/en
Publication of AU2017283720B2 publication Critical patent/AU2017283720B2/en
Priority to AU2023200825A priority Critical patent/AU2023200825A1/en
Assigned to ALEXION PHARMACEUTICALS, INC. reassignment ALEXION PHARMACEUTICALS, INC. Request for Assignment Assignors: PORTOLA PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2017283720C1 publication Critical patent/AU2017283720C1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017283720A 2016-06-17 2017-06-19 Preparation of factor Xa derivatives Active 2038-07-03 AU2017283720C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023200825A AU2023200825A1 (en) 2016-06-17 2023-02-14 Preparation of factor Xa derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
US62/351,841 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200825A Division AU2023200825A1 (en) 2016-06-17 2023-02-14 Preparation of factor Xa derivatives

Publications (3)

Publication Number Publication Date
AU2017283720A1 AU2017283720A1 (en) 2019-01-03
AU2017283720B2 AU2017283720B2 (en) 2022-11-17
AU2017283720C1 true AU2017283720C1 (en) 2024-07-25

Family

ID=60663351

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017283720A Active 2038-07-03 AU2017283720C1 (en) 2016-06-17 2017-06-19 Preparation of factor Xa derivatives
AU2023200825A Pending AU2023200825A1 (en) 2016-06-17 2023-02-14 Preparation of factor Xa derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023200825A Pending AU2023200825A1 (en) 2016-06-17 2023-02-14 Preparation of factor Xa derivatives

Country Status (21)

Country Link
US (4) US10604748B2 (cg-RX-API-DMAC7.html)
EP (3) EP3472314B1 (cg-RX-API-DMAC7.html)
JP (3) JP6959268B2 (cg-RX-API-DMAC7.html)
KR (1) KR102373215B1 (cg-RX-API-DMAC7.html)
CN (3) CN116425860B (cg-RX-API-DMAC7.html)
AU (2) AU2017283720C1 (cg-RX-API-DMAC7.html)
CL (2) CL2018003654A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019000120A2 (cg-RX-API-DMAC7.html)
DK (1) DK3472314T3 (cg-RX-API-DMAC7.html)
EA (1) EA037815B1 (cg-RX-API-DMAC7.html)
ES (2) ES3038834T3 (cg-RX-API-DMAC7.html)
HU (1) HUE054597T2 (cg-RX-API-DMAC7.html)
IL (1) IL263591B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018015873A (cg-RX-API-DMAC7.html)
PE (1) PE20190661A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018502614A1 (cg-RX-API-DMAC7.html)
PL (1) PL3472314T3 (cg-RX-API-DMAC7.html)
PT (1) PT3472314T (cg-RX-API-DMAC7.html)
SG (1) SG11201810915QA (cg-RX-API-DMAC7.html)
SI (1) SI3472314T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017219034A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
EP2948168B1 (en) * 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CN116425860B (zh) * 2016-06-17 2025-03-04 阿雷克森制药公司 因子xa衍生物的制备
JP2021527435A (ja) 2018-06-19 2021-10-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤に対する解毒剤
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029061A1 (en) * 2014-08-20 2016-02-25 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
US7598276B2 (en) 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
EP3824902A1 (en) * 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CN102316893B (zh) 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
SG11201408028YA (en) * 2012-06-14 2015-01-29 Portola Pharm Inc METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
EP2948168B1 (en) * 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
SG11201601221XA (en) * 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
CN116425860B (zh) * 2016-06-17 2025-03-04 阿雷克森制药公司 因子xa衍生物的制备

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029061A1 (en) * 2014-08-20 2016-02-25 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote

Also Published As

Publication number Publication date
EP3926044B1 (en) 2025-06-04
US10954504B2 (en) 2021-03-23
DK3472314T3 (da) 2021-07-26
PH12018502614A1 (en) 2019-09-30
EP4588932A2 (en) 2025-07-23
CN110167575B (zh) 2024-03-15
EP3472314A2 (en) 2019-04-24
EP3926044A1 (en) 2021-12-22
WO2017219034A3 (en) 2019-03-14
EP4588932A3 (en) 2025-10-01
SG11201810915QA (en) 2019-01-30
US20240076642A1 (en) 2024-03-07
WO2017219034A2 (en) 2017-12-21
IL263591A (en) 2019-02-03
PE20190661A1 (es) 2019-05-08
US11845966B2 (en) 2023-12-19
SI3472314T1 (sl) 2021-11-30
US20200208131A1 (en) 2020-07-02
US20210348149A1 (en) 2021-11-11
PT3472314T (pt) 2021-06-18
ES3038834T3 (en) 2025-10-15
IL263591B2 (en) 2023-03-01
KR20190019134A (ko) 2019-02-26
EA037815B1 (ru) 2021-05-25
JP7273918B2 (ja) 2023-05-15
CN116425860B (zh) 2025-03-04
EP3472314B1 (en) 2021-05-05
JP6959268B2 (ja) 2021-11-02
CL2020001733A1 (es) 2020-09-25
US20170369862A1 (en) 2017-12-28
AU2017283720B2 (en) 2022-11-17
AU2023200825A1 (en) 2023-03-16
US10604748B2 (en) 2020-03-31
ES2875538T3 (es) 2021-11-10
JP2019528242A (ja) 2019-10-10
JP2022000477A (ja) 2022-01-04
HUE054597T2 (hu) 2021-09-28
CN118271391A (zh) 2024-07-02
CL2018003654A1 (es) 2019-01-25
BR112018075964A2 (pt) 2019-04-02
CN116425860A (zh) 2023-07-14
JP2023086970A (ja) 2023-06-22
AU2017283720A1 (en) 2019-01-03
KR102373215B1 (ko) 2022-03-10
PL3472314T3 (pl) 2021-11-22
IL263591B (en) 2022-11-01
EA201990052A1 (ru) 2019-05-31
CO2019000120A2 (es) 2019-03-29
MX2018015873A (es) 2019-08-12
CN110167575A (zh) 2019-08-23
CA3027457A1 (en) 2017-12-21
EP3472314A4 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
US20240076642A1 (en) Preparation of factor xa derivatives
JP5037331B2 (ja) 出血性障害の処置のための第ｉｘａ因子
JP2017500027A (ja) 補因子の非存在下で凝固活性を有する、及び／又は、第ｉｘ因子凝固活性が増加した第ｉｘ因子変異体、並びに、出血性疾患を処置するためのその使用
US20050181978A1 (en) Therapeutic use of factor XI
WO2011064247A1 (en) Method of purifying pegylated proteins
CA3027457C (en) Preparation of factor xa derivatives
CA2540986A1 (en) Therapeutic use of factor xi
HK40065948A (en) Preparation of factor xa derivatives
HK40006502B (en) Preparation of factor xa derivatives
BR122025008348A2 (pt) Produto polipeptídico expressado a partir de um construto de polinucleotídeo, composição farmacêutica e uso da referida composição farmacêutica
BR112018075964B1 (pt) Método para preparar um produto de polipeptídeo expressado a partir de um construto de polinucleotídeo, composição farmacêutica e uso da referida composição farmacêutica

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALEXION PHARMACEUTICALS, INC.

Free format text: FORMER OWNER(S): PORTOLA PHARMACEUTICALS, INC.

NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: ANDEXXA ANDEXANET ALFA

Filing date: 20230703

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 MAR 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 MAR 2024

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: ANDEXXA ANDEXANET ALFA

Filing date: 20230703

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: ANDEXXA ANDEXANET ALFA

Filing date: 20230703

Extension date: 20380703